Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3288 - Ipatasertib (GDC-0068), a novel Akt inhibitor, synergizes with anti-microtubule chemotherapic agents in human breast cancer cell lines


10 Oct 2016


Poster display


Carminia Maria Della Corte


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


C.M. Della Corte1, M. Orditura1, A. Diana1, C. Di Mauro2, V. Ciaramella1, F. De Vita1, F. Ciardiello1, F. Morgillo1

Author affiliations

  • 1 Medical Oncology, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 80131 - Napoli/IT
  • 2 Oncology, Azienda Ospedaliera Universitaria Policlinico Federico II-AOU Federico II, 80131 - Napoli/IT


Abstract 3288


Targeting PI3K/Akt/mTOR signaling in cancer is an attractive therapeutic option, and particular the block of Akt can inhibit tumor growth. Ipatasertib (GDC-0068) is a potent inhibitor of all three Akt isoforms in in vitro and in vivo human tumormodels with activated Akt signaling, exhibiting a specific activity on mutant Akt1. Two ongoing trials are evaluating the efficacy of ipatasertib in combination with paclitaxel in neoadjuvant (NCT02301988) or in first line (NCT02162719) therapy in triple negative breast cancer patients. We investigated the role of ipatasertib in combination with anti-microtubule agents vinorelbine, taxanes, and eribulin in breast cancer cell lines.


The efficacy of combined treatment of Ipatasertib (GDC-0068) plus vinorelbine/taxanes/eribulin was evaluated in in vitro models of all breast cancer subtypes (HR and HER2 +/-, Akt wild-type/mutant). We assayed cell proliferation by using MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) and apoptosis by flow-cytometry analysis. The effect on the activation status of proteins downstream of Akt (phospho-S6, S6, phosphor-4EBP1, 4EBP1) and on other intracellular pathways (phospho-MAPK, MAPK, phosphor-MEK, MEK, cleaved PARP, caspase 3, Bcl-2) was analyzed by Western Blot analysis.


A significant synergism of ipatasertib and chemotherapy in terms of anti-proliferative and pro-apoptotic effect was registered, irrespective of HR expression, HER2, and PI3KCA mutational status. These effects were accompanied by inhibition of Akt and MAPK pathways and activation of pro-apoptotic proteins, such as cleaved PARP and caspase 3.


Targeting downstream signaling by blocking Akt with ipatasertib could represent a new strategy to enhance chemotherapy effects in breast cancer models.

Clinical trial identification

Legal entity responsible for the study

Second University of Naples




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings